抗肥満薬の世界市場-2023年～2030年

市場概要

世界の抗肥満薬市場は、2022年に25億米ドルに達し、2023-2030年の予測期間中にCAGR 45.5%で成長し、2030年には437億米ドルに達すると予測されています。

肥満とは、健康に有害な結果をもたらす可能性があるほど体脂肪が過剰に蓄積した健康障害のことです。一般的に肥満とは、体格指数（BMI）が30以上であることを指します。先進国および発展途上国において、最も大きく急速に増加している一般的な健康問題です。抗肥満薬は、肥満の人を助けるために処方される医薬品です。これらの医薬品は、空腹感を抑えたり、代謝を促進したり、食物からの脂肪の吸収を阻害したりすることで機能します。

この市場を牽引しているのは、肥満人口の増加、認知度の向上、市場への製品導入です。需要は、新薬開発のための研究活動や、企業間の合併、拡大、買収、提携を含む市場開拓によって再び押し上げられます。

市場力学

肥満人口の増加が抗肥満薬市場の成長を牽引

肥満人口の増加は、予測期間中の世界の抗肥満薬市場を押し上げると予想されます。例えば、世界肥満連盟が発行したWorld Obesity Atlas 2022によると、2030年までに女性の5人に1人、男性の7人に1人を含む10億人以上が肥満とともに生活すると予測されています。

さらにWHOは2022年3月、世界で10億人以上が太りすぎであり、そのうち6億5,000万人が成人、3億4,000万人が青年、3,900万人が小児であると発表しました。同様にWHOは、2025年までにおよそ1億6,700万人が太りすぎや肥満のために体力が低下すると評価しています。

2023年3月、世界肥満連盟（WOF）は、2035年までに世界人口の半分を占める40億人以上が肥満になるとする報告書を発表しました。さらに、世界肥満連盟が発表した「World Obesity Atlas 2023」によると、予防と治療基準が強化されなければ、過体重と肥満による多国間の経済効果は、2035年までに通年で4兆3,200億米ドルに達すると予想されています。

抗肥満薬の研究活動の活発化が、世界の抗肥満薬市場に成長機会をもたらすと期待される

抗肥満薬に関する調査活動の活発化は、今後数年間、世界の抗肥満薬市場に有望な成長機会をもたらすと期待されています。例えば、2022年6月、抗肥満薬の開発に従事する臨床段階のバイオ製薬会社であるInnovent Biologics（Suzhou）Co. Ltd.は、肥満治療のためのグルカゴン様ペプチド1受容体（GLP-1R）およびグルカゴン受容体（GCGR）デュアルアゴニストであるIBI362の中国における第II相臨床試験（NCT04904913）のトップライン結果を報告しました。

薬剤コストの高さが予測期間中の世界の抗肥満薬市場の妨げに

抗肥満薬のコストが高いことが、予測期間における世界の抗肥満薬市場の成長を妨げると推定されます。例えば、ウェゴビーの4週間コースの指標コストは1カ月当たり1,349ドルですが、保険が適用される個人はそれ以下の金額で済みます。ただし、体重が元に戻らないことを保証するために、生涯にわたって薬を服用し続けることが義務付けられています。

このレポートの詳細- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 肥満人口の増加
    • 市場開拓
  • 抑制要因
    • 高い薬剤費
  • 機会
    • 研究の増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 作用機序別

• 末梢性作用薬
• 中枢作用薬

第8章 薬剤タイプ別

• 処方薬
• OTC薬（市販薬）

第9章 投与経路別

• 経口
• 静脈内／皮下

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋
• 中東・アフリカ
  • 地域別の主な動向

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Eli Lilly and Company
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Bayer AG
• Bristol-Myers Squibb
• Currax Pharmaceuticals LLC
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Norgine BV
• Novo Nordisk AS
• Pfizer Inc.

第14章 付録

• 米国と製品について

Market Overview

Global Anti-Obesity Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2023-2030.

Obesity is a health disorder with surplus body fat gathered to an magnitude that it may generate a harmful consequence on health. It is typically comprehended as owning a body mass index (BMI) of 30 or above. It is distinctively identified as the biggest and rapid-growing general health concern in developed and developing nations. Anti-obesity drugs are pharmaceuticals prescribed to aid individuals who are obese. These medications function by subduing hunger, boosting metabolism, or precluding the absorption of fat from food.

The market is driven by the growing obese population, increasing awareness and product introductions into the market. The demand is again pushed by reasearch activities for new drug developments, and market developments including mergers, expansions, acquisitions and collaborations among market players.

Market Dynamics

The Growing Obese Population Drive the Growth of the Anti-obesity Drugs Market

The growing obese population is expected to boost the global anti-obesity drugs market during the forecast period. For instance, according to the World Obesity Atlas 2022, issued by the World Obesity Federation, over 1 billion individuals globally, including one out of five females and one out of seven males, were expected to be living with obesity by 2030.

Moreover, in March 2022, the WHO issued an article remarking that over 1 billion individuals are overweight globally, of which 650 million are adults, 340 million adolescents, and 39 million children. Likewise, WHO assessed that by 2025, roughly 167 million individuals would be less fit due to being overweight or obese.

Again, in March of 2023, the World Obesity Federation (WOF) published a report remarking that by 2035 more than 4 billion individuals accounting for half the world's population is expected to be obese. Further, the World Obesity Atlas 2023, publicized by World Obesity Federation, indicates that the multinational economic effect of overweight and obesity is expected to attain $4.32 trillion perennial by 2035 if precluding and therapy standards do not enhance.

The Increasing Research Activities for Anti-obesity Drugs are Expected to Present the Global Anti-obesity Drugs Market With Growth Opportunities

Increasing research activities for anti-obesity drugs are expected to present the global anti-obesity drugs market with prospective growth opportunities in the forthcoming years. For instance, in June 2022, Innovent Biologics (Suzhou) Co. Ltd., a clinical-stage biopharmaceutical company engaged in the development of anti-obesity medication, reported its topline outcomes from its Phase II clinical trial (NCT04904913) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China for obesity treatment.

The High Drug Cost is Estimated to Hamper the Global Anti-obesity Drugs Market During the Forecast Period

The high cost of anti-obesity drugs is estimated to hamper the global anti-obesity drug market growth in the forecast period. For instance, a four-week course of Wegovy has an index cost of $1,349 per month, although individuals with insurance that cover the drug disburse less. Provided that individuals are required to remain on the medications for life to assure they do not put weight back on.

For more details on this report - Request for Sample

Segment Analysis

The global anti-obesity drugs market is segmented based on mechanism of action, drug type, route of administration, distribution channel, and region.

The Prescription Drugs Drug Type is Estimated to Dominate the Global Anti-obesity Drugs Market

The prescription drugs drug type is expected to hold around 57.8% of the global market share owing to increased product authorization from distinct regulatory authorities. For instance, in November 2021, Novo Nordisk reported that the European regulatory authority, Committee for Medicinal Products for Human Use (CHMP), embraced a favorable view and advised the commercialization license for Wegovy for chronic weight management in adults with obesity.

Moreover, in June 2022, the U.S. Food and Drug Administration approved Qsymia as an added indication for the planning of constant weight in pediatric patients 12 years old and older who are overweight, as specified by a body mass index (BMI) of 95th percentile or more elevated when standardized for age and sex. Augmenting a low-calorie diet and a more significant workout with Qsymia is suggested.

Geographical Penetration

North America is Estimated to hold Approximately 38.3% of the Market Share by 2030, Owing to Growing Obese Population in this Region

Owing to the growing obese population in the North American region, it is estimated to dominate the global market holding around 38.3% of the market by 2030. For instance, according to the Trust for America's Health's (TFAH) 19th annual report on the country's obesity, State of Obesity 2022- Better Policies for a Healthier America encountered that four out of 10 American adults are obese, and obesity rates persist to ascend nationwide.

Moreover, according to the High Obesity Program (HOP 2023) supported by the CDC, a flawed diet and lower grades of physical exercise impact general fitness and are substantial threats leading to obesity and chronic conditions. Obesity in the United States impacts 100.1 million (41.9%) grown-ups and 14.7 million (19.7%) youngsters and makes up for roughly $147 billion in annual healthcare expenditures.

Competitive Landscape

The major global players in the anti-obesity drugs market include Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, and Pfizer Inc., among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is assumed to have had a moderate impact on the global anti-obesity drugs market, as this region lacks primary market players. Access to health care is majorly affected because of security considerations, limited mobility, damaged supply chains, and mass population eviction. Again, the import and export of fundamental materials' significance is expected to slightly impact the global anti-obesity drugs market growth in the forecast period.

By Mechanism of Action

• Peripherally Acting Drugs
• Centrally Acting Drugs

By Drug Type

• Prescription Drugs
• OTC Drugs

By Route of Administration

• Oral
• Intravenous/Subcutaneous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In October 2022, Eli Lilly and Company, a pharmaceutical corporation, obtained the U.S. Food and Drug Administration (FDA) Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.
• In January 2022, Novo Nordisk AS formed a partnership with the start-up Fauna Bio to investigate the molecules and pathways that regulate metabolism in hibernating creatures in demand to discover unique therapeutic strategies for obesity.

Why Purchase the Report?

• To visualize the global anti-obesity drugs market segmentation based on mechanism of action, drug type, route of administration, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous anti-obesity drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available in excel consisting of key products of all the major players.

The global anti-obesity drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Mechanism of Action
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Obese Population
    • 4.1.1.2. Market Developments
  • 4.1.2. Restraints
    • 4.1.2.1. High Drug Cost
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Research
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Mechanism of Action

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 7.1.2. Market Attractiveness Index, By Mechanism of Action
• 7.2. Peripherally Acting Drugs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Centrally Acting Drugs

8. By Drug Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.1.2. Market Attractiveness Index, By Drug Type
• 8.2. Prescription Drugs*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. OTC Drugs

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Intravenous/Subcutaneous

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan

Australia

• 11.5.7.4. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mechanism of Action
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Eli Lilly and Company*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Bayer AG
• 13.3. Bristol-Myers Squibb
• 13.4. Currax Pharmaceuticals LLC
• 13.5. F. Hoffmann-La Roche AG
• 13.6. GlaxoSmithKline PLC
• 13.7. Merck & Co. Inc.
• 13.8. Norgine BV
• 13.9. Novo Nordisk AS
• 13.10. Pfizer Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Product
• 14.2. Contact Us